AstraZeneca PLC Block listing Interim Review
December 02 2024 - 10:05AM
RNS Regulatory News
RNS Number : 3915O
AstraZeneca PLC
02 December 2024
2 December 2024 15:05 GMT
BLOCK LISTING SIX MONTHLY
RETURN
Information
provided on this form must be typed or printed electronically and
provided to an ris.
(Note: Italicised terms have the
same meaning as given in the Listing Rules.)
Date: 2
December 2024
|
Name of applicant:
|
ASTRAZENECA PLC
|
|
Name of scheme:
|
ASTRAZENECA SHARE OPTION PLAN;
ASTRAZENECA SAVINGS-RELATED SHARE OPTION
PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012
SAVINGS-RELATED SHARE OPTION SCHEME
|
|
Period of return:
|
From:
|
1 JUNE 2024
|
To:
|
30 NOVEMBER 2024
|
|
Balance of unallotted securities
under scheme(s) from previous return:
|
4,090,043
|
|
Plus:
The amount by which the block scheme(s) has been
increased since the date of the last return (if any increase has
been applied for):
|
0
|
|
Less:
Number of securities issued/allotted under
scheme(s) during period (see LR3.5.7G):
|
60,887
|
|
Equals:
Balance under scheme(s) not yet issued/allotted at
end of period:
|
4,029,156
|
|
|
|
|
| |
|
Name of contact:
|
Hannah Tattersall
|
|
Telephone number of
contact:
|
+44 (0)20 3749 5000
|
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is
a global, science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the
Investor Relations Team, please click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
BLRFSUSAEELSELE
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Dec 2023 to Dec 2024
